Abstract
INTRODUCTION: SARS-CoV-2, responsible for the coronavirus disease (COVID-19) pandemic, may impact other systems apart from the respiratory system, including the nervous system. In this systematic review, we aimed to establish the prevalence and determinants of neuropathic pain amongst COVID-19-infected individuals. METHODOLOGY: A literature search in the PubMed database was performed and 11 papers were eligible for inclusion in this systematic review and meta-analysis. RESULTS: The pooled prevalence of COVID-19-related neuropathic pain was 6.7% (95% CI: 4.7-9.5%) for hospitalised patients during the acute phase and 34.3% (95% CI: 14.3-62%) for long COVID patients. The identified risk factors for COVID-19-related neuropathic pain development included depression, COVID-19 severity and azithromycin use. CONCLUSIONS: Neuropathic pain is a very common symptom in long COVID, indicating the urgency for further research in this direction.